BCL2L1 and cancer: Similarly, Bcl-xL is frequently overexpressed in metastatic melanoma and is associated not only with resistance to apoptosis and drug treatment but also with cancer cell stemness, angiogenesis, and immune evasion; indeed, it has been recently reported that it promotes melanoma cell phenotypic plasticity as well as the release of different pro-angiogenic and inflammatory factors from cancer cells, including VEGF, IL-1β e IL-8 [97–103].